# Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

- Link: https://www.thailand-business-news.com/pr-news/abogen-announces-licensing-and-option-agreement-with-novartis-to-advance-mrna-encoded-t-cell-engager-and-other-potential-rna-programs
- Published: 2026-10-02T11:42:00+07:00
- Author: PR Newswire

_Includes worldwide license to ABO2203, Abogen’s mRNA-encoded CD19xCD3 T-Cell Engager

_Agreement also gives Novartis exclusive options to license other potential programs
leveraging Abogen’s RNA proprietary platform_

SUZHOU, China, Oct. 2, 2026 /PRNewswire/ — Abogen Biosciences ("Abogen" or the "
Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced
that it has entered into a licensing and option agreement with Novartis to advance
RNA-encoded therapeutics. The agreement includes an exclusive worldwide license 
to Abogen’s lead asset, ABO2203, as well as options to exclusively license other
potential programs leveraging Abogen’s proprietary RNA platform.

ABO2203 is a novel mRNA-encoded CD19xCD3 T-cell engager with the potential to transform
the treatment landscape for patients with autoimmune diseases. The program is designed
to reset B cells by utilizing mRNA to direct the endogenous production of T-cell
engagers in vivo. This approach offers a highly differentiated mechanism for B-cell
depletion, potentially providing distinct advantages over traditional recombinant
T-cell engagers.

Under the agreement, Novartis will also have the exclusive option to license a number
of next-generation therapeutic assets developed on Abogen’s RNA platform.

"This agreement marks an important milestone for Abogen, underscoring the broad 
potential of our RNA platform to expand beyond prophylactic vaccines," said Bo Ying,
Chief Executive Officer of Abogen. "ABO2203 is the first mRNA-encoded T-cell engager
to enter clinical evaluation for autoimmune diseases, reflecting our commitment 
to delivering differentiated, accessible and scalable therapies for patients with
B-cell-mediated disorders. We are thrilled to be able to accelerate ABO2203 and 
unlock new therapeutic targets through this agreement with Novartis."

"Achieving effective and durable immune reset remains an important goal across a
number of autoimmune diseases," said Fiona Marshall, President of Biomedical Research
at Novartis. "mRNA-encoded T-cell engagers represent an innovative approach that
could complement existing therapeutic modalities by enabling in vivo production 
of these molecules.  We look forward to further developing the potential of ABO2203
and additional possible applications of Abogen’s RNA platform."

Under the terms of the proposed agreement, Abogen will receive an upfront payment
of USD 575 million and, if all options on all programs are exercised, Abogen is 
eligible to receive up to approximately USD 7.2 billion in potential milestone payments,
subject to the achievement of agreed development, regulatory and commercial milestones.
In addition, Abogen may be eligible to receive potential royalties on future product
sales. The transaction is subject to customary closing conditions, including required
regulatory clearances.

**About Abogen BiosciencesAbogen Biosciences focuses on innovative clinical-stage
biotechnology and is dedicated to the discovery and development of transformative
mRNA-based therapeutics. Powered by its proprietary AI- and automation-driven mRNA
and LNP platform, Abogen has established comprehensive, end-to-end capabilities 
spanning mRNA design, formulation development, and large-scale GMP manufacturing.
The Group has built a robust and diversified pipeline in oncology, autoimmune diseases,
and prophylactic vaccines — highlighted by its lead candidate ABO1108, a lyophilized
mRNA shingles vaccine currently undergoing Phase 3 clinical trials in China.

**Forward-looking statementsThis press release contains forward-looking statements,
including statements regarding the potential benefits of the agreement, the development
of ABO2203 and other programs, milestone payments, regulatory progress and future
clinical outcomes. Actual results may differ materially from those expressed or 
implied by these statements due to risks and uncertainties inherent in drug discovery,
clinical development and regulatory review.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs ](http://www.prnasia.com/story/archive/5062480_CN62480_0?rand=184833)
